#METABOLOMICS WORKBENCH eallman_20190808_174524 DATATRACK_ID:1791 STUDY_ID:ST001239 ANALYSIS_ID:AN002058 PROJECT_ID:PR000829 VERSION 1 CREATED_ON August 13, 2019, 4:44 pm #PROJECT PR:PROJECT_TITLE Antimalarial pantothenamide metabolites target acetyl-CoA biosynthesis in PR:PROJECT_TITLE Plasmodium falciparum PR:PROJECT_SUMMARY Malaria eradication is critically dependent on new therapeutics that target PR:PROJECT_SUMMARY resistant Plasmodium parasites and block transmission of the disease. Here, we PR:PROJECT_SUMMARY report the discovery of potent pantothenamide bioisosteres that are active PR:PROJECT_SUMMARY against blood-stage Plasmodium falciparum parasites and that block transmission PR:PROJECT_SUMMARY of sexual stages to the mosquito vector. These compounds were resistant to PR:PROJECT_SUMMARY degradation by serum pantetheinases, showed favorable pharmacokinetic properties PR:PROJECT_SUMMARY and cleared parasites in a humanized mouse infection model of P. falciparum. PR:PROJECT_SUMMARY Metabolomics revealed that CoA biosynthetic enzymes converted pantothenamides PR:PROJECT_SUMMARY into CoA-analogs that interfered with parasite acetyl-CoA anabolism. In vitro PR:PROJECT_SUMMARY generated resistant parasites showed mutations in acetyl-CoA synthetase and PR:PROJECT_SUMMARY acyl-CoA synthetase 11. Introduction and reversion of these mutations in P. PR:PROJECT_SUMMARY falciparum by CRISPR/Cas9 gene editing confirmed the key roles of these enzymes PR:PROJECT_SUMMARY in the sensitivity of the malaria parasite to pantothenamides. These PR:PROJECT_SUMMARY pantothenamide compounds with a unique mode of action may have potential as PR:PROJECT_SUMMARY drugs against malaria parasites. PR:INSTITUTE Penn State PR:LAST_NAME Llinas PR:FIRST_NAME Manuel PR:ADDRESS W126 Millennium Science Complex, University Park, PENNSYLVANIA, 16802, USA PR:EMAIL mul27@psu.edu PR:PHONE (814) 867-3527 #STUDY ST:STUDY_TITLE NMR assignment of synthetic pantothenamides (part-II) ST:STUDY_SUMMARY 1H and 13C NMR of synthesized pantothenamides used for in vitro metabolomics ST:STUDY_SUMMARY studies. ST:INSTITUTE Penn State ST:LAST_NAME Llinas ST:FIRST_NAME Manuel ST:ADDRESS W126 Millennium Science Complex, University Park, PENNSYLVANIA, 16802, USA ST:EMAIL mul27@psu.edu ST:PHONE (814) 867-3527 #SUBJECT SU:SUBJECT_TYPE Other SU:SUBJECT_SPECIES Synthetic #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - 006_1H Spectra:1H NMR Type=CXP18.6-006 SUBJECT_SAMPLE_FACTORS - 006_13C Spectra:13C NMR Type=CXP18.6-006 SUBJECT_SAMPLE_FACTORS - 017_1H Spectra:1H NMR Type=CXP18.6-017 SUBJECT_SAMPLE_FACTORS - 017_13C Spectra:13C NMR Type=CXP18.6-017 SUBJECT_SAMPLE_FACTORS - 026_1H Spectra:1H NMR Type=CXP18.6-026 SUBJECT_SAMPLE_FACTORS - 026_13C Spectra:13C NMR Type=CXP18.6-026 SUBJECT_SAMPLE_FACTORS - 052_1H Spectra:1H NMR Type=CXP18.6-052 SUBJECT_SAMPLE_FACTORS - 052_13C Spectra:13C NMR Type=CXP18.6-052 SUBJECT_SAMPLE_FACTORS - 052_HSQC Spectra:HSQC NMR Type=CXP18.6-052 SUBJECT_SAMPLE_FACTORS - 258_1H Spectra:1H NMR Type=MMV689258 SUBJECT_SAMPLE_FACTORS - 258_13C Spectra:13C NMR Type=MMV689258 SUBJECT_SAMPLE_FACTORS - 968_1H Spectra:1H NMR Type=MMV884968 SUBJECT_SAMPLE_FACTORS - 968_13C Spectra:13C NMR Type=MMV884968 #COLLECTION CO:COLLECTION_SUMMARY Synthesized compounds were freeze dried and resuspended in MeOD between 10-20mM. CO:COLLECTION_SUMMARY Samples were then placed into NMR sample tubes for analysis. CO:SAMPLE_TYPE Synthetic chemistry #TREATMENT TR:TREATMENT_SUMMARY No treatment, these synthetic compounds tested for structure accuracy and TR:TREATMENT_SUMMARY purity. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Several of the original synthesized compounds were in DMSO. This was removed, to SP:SAMPLEPREP_SUMMARY the best of our ability, using a freeze dryer before dissolving in MeOD. #ANALYSIS AN:ANALYSIS_TYPE NMR #NMR NM:INSTRUMENT_NAME Bruker AVIII-HD-500 NM:INSTRUMENT_TYPE FT-NMR NM:NMR_EXPERIMENT_TYPE Other NM:SPECTROMETER_FREQUENCY 500 MHz #END